NCT04109755View on ClinicalTrials.gov

Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

March 31, 2028

Conditions
Rectum CancerRectal Cancer
Interventions
DRUG

Pembrolizumab

5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery

Trial Locations (1)

1205

RECRUITING

Hôpitaux Universitaires de Genève, Geneva

All Listed Sponsors
lead

University Hospital, Geneva

OTHER

NCT04109755 - Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer | Biotech Hunter | Biotech Hunter